Psychiatry

In recent conversations with experts in epilepsy, the impact of stigmatization remains high for patients and ongoing efforts by clinicians to address this issue in the clinical setting has been underscored, despite the global lack of awareness about new treatments and other resources.

Presented at ASH 2023, opioid use disorder in sickle cell disease patients with vaso-occlusive is associated with a longer hospital stay and greater cost.

Mothers with mood disorders—either bipolar disorder, major depressive disorder— or schizophrenia/ schizoaffective disorder are not associated with their offspring’s risk for type 1 diabetes. Results suggest mothers with bipolar disorder tend to develop type 1 diabetes, but data is not clinically significant.

In an interview with HCPLive, Rishi Kakar, MD, discussed how KarXT is a novel molecule unique from currently available schizophrenia treatments.

The FDA will decide on the approval of xanomeline-trospium, a dual M1/M4 muscarinic acetylcholine receptor agonist in the central nervous system, for the treatment of schizophrenia patients by September 2024.

In a new study, the highest socioeconomic group was associated with lower morality rates for all-cause mortality, lower morality from natural causes, and higher mortality from external causes. Although the data does not show a significant link between the role of socioeconomic position with the mortality rate among people with mental disorders.

From 2018 to 2021, the deaths among U.S. pregnant and postpartum women aged 35 – 44 years old more than tripled, a new study found.

At the 14-year follow-up, ADHD medication use was associated with a 4% increased risk of cardiovascular diseases.

After years 1, 3, and 5, patients with diabetic retinopathy patients had increased odds of depression and suicide, patients with glaucoma had increased odds for all mental health conditions with higher odds for suicide or suicide ideation, and patients with AMD had increased odds for depression.

Children of mothers in minority group were associated with a higher likelihood of ASD diagnosis, but only children of White mothers had ASD associated with neighborhood disadvantages.

Ryan Oakley, MD, takes a closer look at the recent history of ketamine in depression. He also explores the differences between ketamine and esketamine.

Eveleigh Wagner, MD, discusses the role of electroconvulsive therapy and transcranial magnetic stimulation in depression treatment.

Brent Necaise, MD, reviews incidence and risk factors of depression, as well as the challenges associated with treatment.

A new study found that 25% of PSG-PTSD were related to metabolic traits.

Adults with ADHD have greater reduction of symptoms with regulatory licensed doses of stimulants than unlicensed doses.

Two pivotal phrase 3 centanafadine trials show positive outcomes for children and adolescents with ADHD.

Papola comments on the study he led which found that cognitive behavior therapy is the most effective form of treatment for GAD.

The rates of pediatric and adolescent treatment for depression, anxiety, ADHD, and behavior disorders vary by age, income level, and region.

CBT is the most effective treatment for GAD, according to new network meta-analyses that compared several psychotherapies.

Adult ADHD is associated with a 2.77-fold increased risk of dementia, according to new research.

Solriamfetol could potentially serve as a new ADHD treatment if future research goes positively.

Solriamfetol, typically used to treat narcolepsy and sleep apnea, has demonstrated it can reduce ADHD symptoms with no adverse cardiovascular effects.

Participants with PTSD in a new study heard voices more significantly than did patients with schizophrenia and schizoaffective disorder, according to investigators.

A new analysis was unable to provide conclusive comparisons between the 2 methods of psychotherapy delivery, despite robust data.

Regarding teachers’ responses to handle anxiety in students with autism spectrum disorder, 33.3% teachers promote anxiety and 37.1% promote autonomy.